Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Schenone

Showing results (91-100 of 173) with videos related to

Pageof 18
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 4, 2012
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitorsMarco Radi, Federico Falchi, Anna Garbelli, et al.
Brain Sciences|July 2, 2021
Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma CellsAna Kostić, Sofija Jovanović Stojanov, Ana Podolski-Renić, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2007
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agentsMarco Radi, Emmanuele Crespan, Giorgia Botta, et al.
Bioorganic & Medicinal Chemistry|April 14, 2009
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitorsOlga Bruno, Chiara Brullo, Francesco Bondavalli, et al.
International Journal of Pharmaceutics|February 1, 2021
Pyrazole[3,4-d]pyrimidine derivatives loaded into halloysite as potential CDK inhibitorsMarina Massaro, Giampaolo Barone, Viviana Barra, et al.
ACS Medicinal Chemistry Letters|May 22, 2020
Development of Pyrazolo[3,4-<i>d</i>]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma MultiformeChiara Greco, Vincenzo Taresco, Amanda K Pearce, et al.
European Journal of Medicinal Chemistry|January 12, 2017
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against GlioblastomaFrancesca Musumeci, Anna Lucia Fallacara, Chiara Brullo, et al.
Molecular Medicine Reports|October 18, 2017
Matrine in association with FD‑2 stimulates F508del‑cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809Barbara Marengo, Andrea Speciale, Lisa Senatore, et al.
Pharmaceutics|December 23, 2023
New Insights into the LANCL2-<b>ABA</b> Binding Mode towards the Evaluation of New LANCL AgonistsNaomi Scarano, Francesco Di Palma, Nicola Origlia, et al.
Medchemcomm|July 4, 2017
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanomaKerem M Senses, Mehdi Ghasemi, Muhammad W Akbar, et al.
Pageof 18

Showing results (91-100 of 173) with videos related to

Sort By:
Pageof 18
Bioorganic & Medicinal Chemistry Letters|February 4, 2012
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitorsMarco Radi, Federico Falchi, Anna Garbelli, et al.
Brain Sciences|July 2, 2021
Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma CellsAna Kostić, Sofija Jovanović Stojanov, Ana Podolski-Renić, et al.
Bioorganic & Medicinal Chemistry Letters|December 15, 2007
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agentsMarco Radi, Emmanuele Crespan, Giorgia Botta, et al.
Bioorganic & Medicinal Chemistry|April 14, 2009
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitorsOlga Bruno, Chiara Brullo, Francesco Bondavalli, et al.
International Journal of Pharmaceutics|February 1, 2021
Pyrazole[3,4-d]pyrimidine derivatives loaded into halloysite as potential CDK inhibitorsMarina Massaro, Giampaolo Barone, Viviana Barra, et al.
ACS Medicinal Chemistry Letters|May 22, 2020
Development of Pyrazolo[3,4-<i>d</i>]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma MultiformeChiara Greco, Vincenzo Taresco, Amanda K Pearce, et al.
European Journal of Medicinal Chemistry|January 12, 2017
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against GlioblastomaFrancesca Musumeci, Anna Lucia Fallacara, Chiara Brullo, et al.
Molecular Medicine Reports|October 18, 2017
Matrine in association with FD‑2 stimulates F508del‑cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809Barbara Marengo, Andrea Speciale, Lisa Senatore, et al.
Pharmaceutics|December 23, 2023
New Insights into the LANCL2-<b>ABA</b> Binding Mode towards the Evaluation of New LANCL AgonistsNaomi Scarano, Francesco Di Palma, Nicola Origlia, et al.
Medchemcomm|July 4, 2017
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanomaKerem M Senses, Mehdi Ghasemi, Muhammad W Akbar, et al.
Pageof 18